1.Diagnosis and management of prostate cancer.
Journal of the Korean Medical Association 2015;58(1):5-6
No abstract available.
Diagnosis*
;
Prostatic Neoplasms*
2.PSA and prostatic cancer
Journal of Medical Research 1998;5(1):50-56
PSA is a protein with antigen properties, generated by epicyte of prostate gland, excretes into microtube and then comes mostly into sperma, litter into serum and lymphatic fluid with unclear mechanism. PSA in these are determined by chemicoimmune. The average human serum PSA is 2.5 ng/ml. PSA is specific antigen with cells of prostate-gland and the application of PSA test in diagnostics and monitoring is significant in clinical. Especially, the level of PSA help to early diagnose the prostatic cancer and distinguished diagnose between prostatomegaly and prostatic cancer.
Prostatic Neoplasms
;
Antigens
;
diagnosis
3.Value of Hypoechoic Lesions in Transrectal Ultrasonography for Diagnosis of Prostate Cancer.
Korean Journal of Urology 2000;41(4):500-504
No abstract available.
Diagnosis*
;
Prostate*
;
Prostatic Neoplasms*
;
Ultrasonography*
4.Primary Neoplasm in a Vesical Diverticulum: A Case Report.
Eui Hyun CHANG ; No Gyo SEO ; Sung Choon LEE
Korean Journal of Urology 1986;27(2):323-326
Primary neoplasms arising in vesical diverticula are rare and present special problems in diagnosis and treatment. We report a case of primary carcinoma arising in vesical diverticula with associated benign prostatic hypertrophy.
Diagnosis
;
Diverticulum*
;
Prostatic Hyperplasia
;
Urinary Bladder Neoplasms
5.EPCA-2 in the early diagnosis of prostate cancer.
National Journal of Andrology 2010;16(6):552-555
More and more clinical evidence has confirmed the limitations of the use of serum PSA in the screening, detection and treatment of prostate cancer, and scientists are continuously seeking for new biomarkers of the disease. The discovery of early prostate cancer antigen 2 (EPCA-2) has provided a new base for the screening, detection, treatment and follow-up of prostate cancer.
Antigens, Neoplasm
;
analysis
;
Early Diagnosis
;
Humans
;
Male
;
Prostatic Neoplasms
;
diagnosis
6.Prostate carcinoma presenting with symptoms mimicking rectal cancer.
Zhenbang LIU ; Quormeng LEONG ; Hai Yi TEO ; Yee Mun LEE
Annals of the Academy of Medicine, Singapore 2014;43(5):285-287
Aged
;
Carcinoma
;
diagnosis
;
Diagnosis, Differential
;
Humans
;
Male
;
Prostatic Neoplasms
;
diagnosis
;
Rectal Neoplasms
;
diagnosis
7.Prospects for early diagnosis of prostate cancer by detection of plasma DNA.
National Journal of Andrology 2004;10(7):543-546
A major problem for the early diagnosis of prostate cancer is the lack of clinically useful tests for screening a preclinical and asymptomic population without resort to invasive diagnostic procedures. Recent studies have demonstrated the possibility to detect genetic alterations in plasma or serum DNA from patients with prostate cancer or other cancers. Quantification and molecular event are associated with advanced stages and circulating tumor cells. These results indicate a new approach to the early diagnosis and monitoring of prostate cancer by non-invasive screening procedures based on the analysis of genetic changes in plasma.
DNA
;
blood
;
Humans
;
Male
;
Prostatic Neoplasms
;
blood
;
diagnosis
8.Caveolin-1: a novel biomarker for prostate cancer.
Wei-Sun HUANG ; Run-Jie WANG ; Jun-Li DING ; Chao-Ying LIU ; Jing-Hua WANG
National Journal of Andrology 2012;18(7):635-638
For lack of the biomarker, early diagnosis of prostate cancer is often difficult. Caveolin-1 (Cav-1) is an important oncogene and a major structural coat protein of caveolae, which is involved in multiple cellular functions including molecular transport, cell adhesion, and signal transduction, as well as in the development and progression of prostate cancer. Cav-1 is secreted as a biologically active molecule that promotes cell survival and angiogenesis within the tumor microenvironment, and is overexpressed in the metastatic and primary sites of human prostate cancer. Secreted Cav-1 can be detected in the peripheral blood, and its expression level has an indicative value in the diagnosis and prognosis of prostate cancer. This review focuses on the structure and biological characteristics of Cav-1 and its correlation with prostate cancer.
Biomarkers, Tumor
;
Caveolin 1
;
Humans
;
Male
;
Prostatic Neoplasms
;
diagnosis
9.PSA-based screening for prostate cancer: a comparative analysis.
National Journal of Andrology 2013;19(6):559-562
PSA-based screening has always been one of the controversial topics among urological researchers. In spite of its benefit in detecting early prostate cancer, PSA-based screening may not only result in widespread overdiagnosis and overtreatment of an often indolent disease, which is life-threatening in only a minority of patients, but also subject participators to such complications as erectile dysfunction and incontinence. Besides, whether PSA-based screening can reduce prostate cancer specific mortality has received considerable attention. This review offers a comparative analysis of recent studies on PSA-based screening for prostate cancer.
Humans
;
Male
;
Prostate-Specific Antigen
;
blood
;
Prostatic Neoplasms
;
blood
;
diagnosis
10.DNA methylation and prostate cancer.
Shui-Gen ZHOU ; Ying-Hao SUN ; Jian-Ping GAO
National Journal of Andrology 2007;13(12):1108-1112
DNA methylation is a common event in malignancies and implicated in tumor initiation and progression. There is a battery of genes involved in critical cell processes such as DNA damage repair, which are hypermethylated in prostate cancer. DNA methylation has also been found in premalignant lesions such as prostatic intraepithelial neoplasia, but to a less extent compared with that in prostate cancer. Intensive study on DNA methylation would provide a new opportunity for the early diagnosis, prognosis and treatment of prostate cancer.
DNA Methylation
;
Humans
;
Male
;
Prognosis
;
Prostatic Neoplasms
;
diagnosis
;
genetics